Helix BioPharma Corp. (HBP.TO)

$0.22

-0.08 (-26.67%)
Rating:
Recommendation:
-
Symbol HBP.TO
Price $0.22
Beta -0.039
Volume Avg. 0.03M
Market Cap 38.356M
Shares () -
52 Week Range 0.17-0.95
1y Target Est -
DCF Unlevered HBP.TO DCF ->
DCF Levered HBP.TO LDCF ->
ROE 313.52% Strong Buy
ROA -340.34% Strong Sell
Operating Margin -
Debt / Equity -221.36% Sell
P/E -
P/B -16.84 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Heman Chao
Healthcare
Biotechnology
Toronto Stock Exchange

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.